HIỆU QUẢ VINORELBINE DẠNG VIÊN UỐNG ĐIỀU TRỊ UNG THƯ VÚ TÁI PHÁT, DI CĂN TRONG ĐẠI DỊCH COVID-19

Abstract

Background: Breast cancer ranks among the most prevalent cancers in women. There are many options of treatment for patients in stage IV. Many trials show the non inferior between oral and intravenous administration. Oral regimens show benefit in saving patient’s time, finance and covenience. However there are not many researches about efficacy and toxicity. Objective: Evaluate the efficacy and toxicity of oral vinorelbine monotherapy in treating patients with recurrent and metastatic breast cancer. Material and Methods: The study entails a case series of 23 patients diagnosed with recurrent/metastatic breast cancer confirmed via pathology and imaging, treated with oral vinorelbine monotherapy at the Oncology Center - Cho Ray Hospital from January 1, 2021, to December 31, 2021. Results: The average treatment duration was 4.7 months. The disease stabilization rate after 3 months was 52.2%, with partial response at 13% and complete response at 4.3%. The disease stabilization rate after 6 months was 40%. The median disease-free survival time was 4.0 months. Leukopenia toxicity was observed in 39.1%, with Grade 2 and 3 toxicities at 44.4% and 33.3% respectively. Elevated liver enzymes occurred in 34.8%, primarily Grade 1 at 87.5%. Conclusion: Vinorelbine monotherapy demonstrates favorable and well-tolerated treatment outcomes.